Rapid Response Home Care as an Alternative to Acute Admission

NCT07458763 | Active Not Recruiting

• 1 other identifier: Hospital at Home: 1
• Study Type: interventional
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

This single-center, randomized, unblinded quality-improvement study evaluates whether a structured home-based rapid response team (RRT) intervention can safely reduce total hospital days among adults referred to the emergency department with suspected infection. Patients referred from general practitioners or the regional medical helpline (1813) between 09:00 and 22:00 are randomized 1:1 using Zelen's design to either standard in-hospital evaluation or a home-based assessment pathway delivered by a mobile clinical response team.

Conditions

Infection

Keywords

hospital at home; admission avoidance; rapid response team; home-based treatment; acute hospital-level care at home; infection

Outcome Measures

Primary Outcomes (1)

• Days Alive Outside of Hospital

  Number of days alive outside of hospital 30 days after initial referral (time of inclusion), including days receiving treatment at home.

  30 days from inclusion

Secondary Outcomes (41)

• Suspected infection focus

  At initial clinical assessment (baseline, prior to initiation of treatment), day 0.

• Early Warning Score, initial assessment

  At initial clinical assessment (baseline, prior to initiation of treatment), day 0

• Contact from CTU to the patient (Intervention-group)

  Index home visit (day 0)

• Intitial assesment at home accepted by patient (Intervention-group)

  Index home visit (day 0)

• Response-time for inititial contact (Intervention-group)

  Index home visit (day 0)

Study Arms (2)

Home-based treatment

EXPERIMENTAL

The intervention group

Other: Admission avoidance Hospital at Home

Standard care

NO INTERVENTION

The control group

Interventions

Admission avoidance Hospital at Home OTHER

The intervention group is evaluated in their homes by a mobile rapid response team to determine whether they can be safely treated at home instead of being admitted to the hospital. If deemed suitable, the patient receives treatment at home.

Home-based treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years or older
• Referred with suspected infection
• Patients must be able to provide informed consent
• Category C or D transports (non-emergency patient transport) and self-transported patients

You may not qualify if:

• Category A and B transport (emergency and urgent patient transport)
• Suspected meningitis
• Suspected sepsis
• Suspected tropical disease
• Suspected other time-critical infection
• Immunodeficiency
• Ongoing treatment with immunosuppressive/immunomodulating/chemotherapy treatment

Sponsors & Collaborators

• Copenhagen University Hospital at Herlev: lead

Study Sites (1)

University Hospital of Copenhagen Herlev

Herlev, Denmark

Location

MeSH Terms

Conditions

Infections

Study Officials

• Kasper K Iversen, MD, Prof.

  University Hospital of Copenhagen Herlev

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Model Details: This study is a randomized clinical non-blinded trial. Participants will be randomized in the ratio 1:1 using Zelen's design.

Study Record Dates

• First Submitted: February 20, 2026
• First Posted: March 9, 2026
• Study Start: September 1, 2025
• Primary Completion: June 1, 2026
• Study Completion: June 1, 2026
• Last Updated: March 11, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

DK (1)